J&J faces diminished blockbuster-drug pipeline

Article Abstract:

Currently, Johnson & Johnson, New Jersey, co-markets EPO for anemia treatment with Amgen, Inc. of California. An arbitration panel ruled on the drug's successor, NESP, to be marketed solely by Amgen once it is through clinical trials and approved by the FDA. J&J claims the ruling will have little impact, especially in the near-term. Meanwhile, new drugs expected from J&J are for treating heartburn, Alzheimer's and MS. The firm will probably also partner with other drug firms on some products while it continues developing new drugs of its own.

Comment:

Co. loses right to market or co-market new anemia drug still in trials

United States, Marketing procedures, Company Planning/Goals, Pharmaceutical Preparation Manufacturing, Pharmaceutical preparations, Care and treatment, Marketing, Anemia, Johnson & Johnson, JNJ

---

SmithKline is expected to sell two units; sale of pharmacy-benefits, clinical-lab businesses increases focus on drugs

Article Abstract:

With no new blockbuster drugs to bring to market anytime soon, Smith Kline Beecham PLC is selling two of its units so it can better concentrate on its core business. Having bought Diversified Pharmaceuticals Services Inc. in 1994 for $2.3 billion, the company will sell it at a loss to competitor Express Scripts Inc., for less than $1 billion. It will also sell its clinical-laboratories division for about $1 billion to Quest Diagnostics Inc.

Comment:

Firm will take a loss and move on

United Kingdom, Asset sales & divestitures, Drugs & Pharmaceuticals, Pharmaceutical and Medicine Manufacturing, Drugs, Mergers, acquisitions and divestments, Medical laboratories, Biomedical laboratories, SmithKline Beecham PLC, Prescription drug plans

---

Similar abstracts:

• Abstracts: Japanese phone giant buys a U.S. stake. Ameritech to sell half of wireless business to GTE. Bell Atlantic and Airtouch stocks slip on uncertainty over merger
• Abstracts: Teaching the world to take notice. Lotus expects applet to take bits out of Microsoft in small bites
• Abstracts: Yahoo's quarter net tops expectations. Microsoft bids for business of web users. This time, it's the barbarians at the Web: In hyperdrive, Excite's CEO stakes a claim
• Abstracts: Mentor makes a hostile bid for Quicken. Two makers of phone gear join forces: Tellabs moves to buy Ciena for $7.3 billion
• Abstracts: Arco expected to sell unit to Lyondell. Hercules to acquire BetzDearborn

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.